By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Cost of Injection Jumps from $15 to $1,500
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Health Reform > Cost of Injection Jumps from $15 to $1,500
BusinessHealth Reform

Cost of Injection Jumps from $15 to $1,500

JohnCGoodman
JohnCGoodman
Share
2 Min Read
SHARE

The following is from an AP story. See also Merrill Goozner’s comments here.

A drug for high-risk pregnant women has cost about $10 to $20 per injection. Next week, the price shoots up to $1,500 a dose, meaning the total cost during a pregnancy could be as much as $30,000.

That’s because the drug, a form of progesterone given as a weekly shot, has been made cheaply for years, mixed in special pharmacies that custom-compound treatments that are not federally approved ….. But recently, KV Pharmaceutical of suburban St.Louis won government approval to exclusively sell the drug, known as Makena (Mah-KEE’-Nah). ….. The cost is justified to avoid the mental and physical disabilities that can come with very premature births, said KV Pharmaceutical chief executive Gregory J. Divis Jr. The cost of care for a preemie is estimated at $51,000 in the first year alone.To get FDA approval, the company is spending hundreds of millions of dollars in additional research, including an international study involving 1,700 women, Divis said. The FDA last month signed off and gave Makena orphan drug status. That designation ensures Ther-Rx will be the sole source of the drug for seven years.

More Read

The $78 Pill
Medicaid Should Not Impoverish Doctors and Hospitals
Telemedicine’s Achilles’ Heel: The Telephone
Merging Modern and Alternative Methods for Complete Healing
What If Shared Decision Making Costs More?

Last month, KV sent cease-and-desist letters to compounding pharmacies, telling them they could face FDA enforcement actions if they kept making the drug.

TAGGED:health care businesshealth care reform
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

mri technology
Why Preventive MRI Maintenance Is Essential for Hospitals
Business Hospital Administration
July 24, 2026
senior on computer
Health and Digital Safety Risks Older Adults Should Know
Senior Care
July 24, 2026
The Riskiest Part of Getting Sick Isn't the Diagnosis. It's the Handoff
The Riskiest Part of Getting Sick Isn’t the Diagnosis. It’s the Handoff
Health
July 20, 2026
Patient Acquisition and digital-marketing
The Future of Patient Acquisition: Modern SEO & Digital Marketing for Dermatology Practices
Health Marketing Medical Innovations Technology
July 20, 2026

You Might also Like

Physician Salaries Represent 8% of Total US Healthcare Cost

June 3, 2011
patient data
Global HealthcareHospital AdministrationMedical EthicsMedical RecordsPolicy & Law

The Importance of Keeping Patient Information Secure

May 22, 2014

Penalizing Hospitals for Readmissions: Will It Work?

December 4, 2012

The Interview: Some Lessons for Healthcare PR

December 29, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?